Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07263689 +/- Sasanlimab in Advanced Solid Tumors
NCT05061537Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- Prophylactic Vaccines, Oncolytic Viruses, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of oncolytic vaccinia virus PF-07263689 in renal cell carcinoma (RCC), melanoma, non-small cell lung cancer (NSCLC) and 7 more (5 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Dose Limiting Toxicities up to 28 days, Number of Participants With Treatment Emergent Adverse Events up to 2 years and 2 more. Started Oct 2021; status: terminated.
02
Drugs
oncolytic vaccinia virus PF-07263689
03
Conditions
renal cell carcinoma (RCC)melanomanon-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)bladder cancer
Beyond the preview
Go deeper on NCT05061537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05061537.